Simplex Trading
ABUS icon

Simplex Trading’s Arbutus Biopharma ABUS Stock Holding History

Simplex Trading’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$214K Sell
47,600
-12,800
-21% -$56K ﹤0.01% 4224
2025
Q4 		$291K Buy
60,400
+40,800
+208% +$183K ﹤0.01% 3852
2025
Q3 		$88K Sell
19,600
-9,000
-31% -$33.1K ﹤0.01% 5891
2025
Q2 		$88K Buy
28,600
+8,700
+44% +$28.9K ﹤0.01% 5357
2025
Q1 		$69K Sell
19,900
-13,100
-40% -$43.7K ﹤0.01% 5455
2024
Q4 		$107K Buy
33,000
+15,600
+90% +$57.4K ﹤0.01% 5103
2024
Q3 		$66K Buy
17,400
+2,600
+18% +$9.97K ﹤0.01% 5625
2024
Q2 		$45K Sell
14,800
-50,300
-77% -$151K ﹤0.01% 6189
2024
Q1 		$167K Buy
65,100
+60,700
+1,380% +$157K ﹤0.01% 5045
2023
Q4 		$11K Sell
4,400
-6,200
-58% -$12.1K ﹤0.01% 7336
2023
Q3 		$21K Sell
10,600
-3,000
-22% -$6.29K ﹤0.01% 6562
2023
Q2 		$31K Sell
13,600
-6,400
-32% -$16.7K ﹤0.01% 6310
2023
Q1 		$60K Sell
20,000
-11,400
-36% -$32.2K ﹤0.01% 5705
2022
Q4 		$73K Buy
31,400
+11,300
+56% +$27K ﹤0.01% 5421
2022
Q3 		$38K Sell
20,100
-58,300
-74% -$137K ﹤0.01% 6784
2022
Q2 		$212K Sell
78,400
-231,600
-75% -$593K ﹤0.01% 4532
2022
Q1 		$923K Sell
310,000
-34,500
-10% -$106K ﹤0.01% 3019
2021
Q4 		$1.34M Buy
344,500
+178,600
+108% +$694K ﹤0.01% 2478
2021
Q3 		$519K Hold
165,900
– – ﹤0.01% 4054
2021
Q2 		$502K Buy
+165,900
New +$514K ﹤0.01% 4157
2021
Q1 		– Sell
-1,872
Closed -$664K – 8634
2020
Q4 		$664K Buy
1,872
+1,013
+118% +$3.55K ﹤0.01% 3080
2020
Q3 		$268K Buy
+859
New +$2.61K ﹤0.01% 3733
2020
Q2 		– Sell
-13
Closed -$1K – 7487
2020
Q1 		$1K Buy
+13
New +$35 ﹤0.01% 7300
2019
Q4 		– Sell
-16
Closed -$2K – 7184
2019
Q3 		$2K Sell
16
-2
-11% -$3 ﹤0.01% 6881
2019
Q2 		$3K Buy
+18
New +$46 ﹤0.01% 6609
2019
Q1 		– Sell
-10
Closed -$3K – 7033
2018
Q4 		$3K Sell
10
-97
-91% -$478 ﹤0.01% 6382
2018
Q3 		$101K Buy
107
+7
+7% +$70 ﹤0.01% 4417
2018
Q2 		$73K Buy
+100
New +$595 ﹤0.01% 4639
2017
Q4 		– Sell
-40
Closed -$6K – 5882
2017
Q3 		$6K Buy
+40
New +$171 ﹤0.01% 4185
2017
Q2 		– Sell
-61
Closed -$1K – 5971
2017
Q1 		$1K Sell
61
-1,163
-95% -$3.23K ﹤0.01% 5512
2016
Q4 		$66K Buy
1,224
+890
+266% +$2.59K ﹤0.01% 1883
2016
Q3 		$32K Buy
334
+137
+70% +$535 ﹤0.01% 2508
2016
Q2 		$23K Buy
197
+15
+8% +$63 ﹤0.01% 2761
2016
Q1 		$20K Buy
182
+155
+574% +$554 ﹤0.01% 2782
2015
Q4 		$20K Hold
27
– – ﹤0.01% 2681
2015
Q3 		$17K Sell
27
-95
-78% -$842 ﹤0.01% 2945
2015
Q2 		$45K Buy
122
+10
+9% +$152 ﹤0.01% 1772
2015
Q1 		$35K Buy
112
+25
+29% +$512 ﹤0.01% 1820
2014
Q4 		$17K Buy
+87
New +$1.5K ﹤0.01% 2168

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Simplex Trading's ABUS Position: Q1 2026 in Review

Simplex Trading reduced its Arbutus Biopharma (ABUS) stake by 30% in Q1 2026, selling an estimated $29K and leaving 15,574 shares worth $70.1K. The position accounts for ﹤0.01% of the portfolio, ranked #5494.

Simplex Trading first reported a position in ABUS in Q1 2015 and has held it in 39 quarters since. The position peaked at $785K in Q4 2021. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Simplex Trading held 15,574 shares of Arbutus Biopharma worth $70.1K as of Q1 2026.
  • Simplex Trading sold 6,629 Arbutus Biopharma shares in Q1 2026, an estimated $29K.
  • Arbutus Biopharma made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #5494 holding.
  • Simplex Trading first reported a position in Arbutus Biopharma in Q1 2015 and has held it in 39 quarters since.
  • Simplex Trading's Arbutus Biopharma position peaked at $785K in Q4 2021.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.